tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Alan Carr, 96 are a BUY (87.27%), 14 are a HOLD (12.73%).
Analyst Alan Carr, carries an average stock price target met ratio of 68.46% that have a potential upside of 38.31% achieved within 471 days. Previously, Alan Carr worked at NEEDHAM.
Alan Carr’s has documented 219 price targets and ratings displayed on 29 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on RYTM, Rhythm Pharmaceuticals at 10-Dec-2025.
Analyst best performing recommendations are on GNCA (GENOCEA BIOSCIENCES).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 11-Jun-2026
$60
$5.08 (9.25%)
$32
1 months 19 days ago
(11-Jun-2026)
8/9 (88.89%)
$9.77 (19.45%)
254
Buy Since 18-Apr-2024
$82
$27.08 (49.31%)
$77
2 months 24 days ago
(06-May-2026)
10/19 (52.63%)
$26.92 (48.87%)
160
Buy Since 17-Jan-2018
$110
$55.08 (100.29%)
$105
4 months 13 days ago
(17-Mar-2026)
27/36 (75%)
$59.91 (119.60%)
235
Buy Since 28-Oct-2019
$76
$21.08 (38.38%)
$74
5 months 13 days ago
(17-Feb-2026)
2/16 (12.5%)
$22.83 (42.94%)
24
Buy Since 16-Feb-2022
$82
$27.08 (49.31%)
$80
5 months 17 days ago
(13-Feb-2026)
8/27 (29.63%)
$28.93 (54.51%)
214
What Year was the first public recommendation made by Alan Carr?
